Evidence map›Paper›PMID 40676109›Full record

Trial reportScientific reports2025

Efficacy and safety of Latilactobacillus sakei LB-P12 in patients with knee osteoarthritis: an exploratory randomized, double-blind, placebo-controlled clinical trial.

Bo-Kyung Shine, Qing Li, Mikyung Song, Kyoungsub Song, Jaeseok Shim, Seong-Ho Han

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Heat-TreatedCells · 2026
    Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bo-Kyung Shine *Department of Family Medicine, College of Medicine, Dong-A University, 26 Daesingongwon-ro, Seo-gu, Busan, 49201, Republic of Korea.
Qing Li *Department of Family Medicine, College of Medicine, Dong-A University, 26 Daesingongwon-ro, Seo-gu, Busan, 49201, Republic of Korea.
Mikyung SongR&D Center, LISCure Biosciences Inc., Seongnam, Republic of Korea.
Kyoungsub SongR&D Center, LISCure Biosciences Inc., Seongnam, Republic of Korea.
Jaeseok ShimR&D Center, LISCure Biosciences Inc., Seongnam, Republic of Korea.
Seong-Ho HanDepartment of Family Medicine, College of Medicine, Dong-A University, 26 Daesingongwon-ro, Seo-gu, Busan, 49201, Republic of Korea. handsomdr@hanmail.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Knee osteoarthritis (OA) is a prevalent degenerative joint disease among middle-aged and older adults, leading to chronic pain, functional limitations, and decreased quality of life. While probiotics have shown anti-inflammatory potential in preclinical studies, their therapeutic role in OA has not been well established in human research. This exploratory randomized controlled trial (RCT) aimed to evaluate the efficacy and safety of Latilactobacillus sakei LB-P12 in improving knee OA symptoms. In this randomized, double-blind, placebo-controlled trial, 100 participants aged 40-75 years with chronic knee pain were assigned to receive either LB-P12 (350 mg/day, 10 billion CFU) or placebo for 12 weeks. The primary outcome was the change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores. Secondary outcomes included visual analog scale (VAS) scores for pain, inflammatory markers (CRP, ESR, IL-1β, IL-6, TNF-α), cartilage degradation biomarkers (COMP), joint space width, and health-related quality of life (EQ-5D-5L). Safety was evaluated using laboratory tests and vital signs. After 12 weeks, the LB-P12 group showed significantly greater improvements in WOMAC total scores and VAS pain scores compared to the placebo group. All three WOMAC subdomains-pain, stiffness, and physical function-showed consistent reductions. Inflammatory cytokines, particularly IL-1β, were significantly reduced in the LB-P12 group. Quality of life also improved significantly. No adverse events or clinically meaningful abnormalities in laboratory values were observed. This exploratory RCT suggests that daily supplementation with LB-P12 is safe and may offer potential benefits in reducing knee pain and improving physical function and quality of life in individuals with knee OA. Further large-scale and long-term RCTs are needed to confirm these findings and elucidate the underlying mechanisms.

Indexed as

Osteoarthritis, KneeProbioticsAdultAgedDouble-Blind MethodFemaleHumansMaleMiddle AgedPain MeasurementQuality of LifeTreatment OutcomeExploratory RCTHuman clinical trialInflammationJoint cartilageLatilactobacillus sakei LB-P12Osteoarthritis

Identifiers

PMID40676109
PMCPMC12271348

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.